Search results for "Treatment persistence"

showing 2 items of 2 documents

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

2019

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

Long actingMaleAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Psychiatry and Mental Health; Biological PsychiatryAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment OutcomePersonalizedAripiprazole0302 clinical medicineRetrospective StudieDelayed-Action PreparationMaintenaMiddle AgedhumanitiesClinical PracticeTreatment OutcomeItalySchizophreniaPsychiatry and Mental HealthAripiprazoleFemaleBiological psychiatrymedicine.symptomManiaHumanmedicine.drugAntipsychotic AgentsAdultmedicine.medical_specialtyMedication AdherencePersistence03 medical and health scienceshealth services administrationInternal medicinemental disordersmedicineTreatment persistenceHumansBiological PsychiatryRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized;030227 psychiatryAntipsychotic AgentLong actingAdherenceDelayed-Action PreparationsSchizophreniabusiness030217 neurology & neurosurgery
researchProduct

POS1021 THE PsABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INH…

2021

Background:There are still unmet needs in the treatment of psoriatic arthritis (PsA), including in terms of treatment persistence, which is a function of effectiveness, safety and patient satisfaction. Ustekinumab (UST) was the first new biologic drug to be developed for the treatment of PsA after tumour necrosis factor inhibitors (TNFi).Objectives:To compare treatment persistence, effectiveness and safety of UST and TNFi in Italian patients within the PsABio cohort.Methods:PsABio (NCT02627768) is an observational study of 1st/2nd/3rd-line UST or TNFi treatment in PsA in 8 European countries. The current analysis set includes 222 eligible patients treated in 15 Italian centres, followed to …

medicine.medical_specialtybusiness.industryImmunologySignificant differenceClinical diseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCurrent analysisUnmet needsPsoriatic arthritisRheumatologyInternal medicineUstekinumabTreatment persistenceImmunology and AllergyMedicineIn patientbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct